What Is Exosome Therapy?
Exosomes are submicroscopic vesicles that the body's cells produce and release continuously as part of an intricate biological communication network. Rather than acting directly on tissue themselves, they serve as carriers, transporting proteins, lipids, and genetic material, including RNA, from cell to cell, transmitting the instructions that govern tissue repair, immune regulation, and inflammation management. The exosomes used in clinical treatment are derived from donor mesenchymal stem cells and manufactured under tightly controlled laboratory conditions. The therapy does not introduce living cells into the body. Instead, it delivers the molecular signals those cells would naturally produce—growth factors, cytokines, and regulatory RNA—giving the body's own cells the biological instructions they need to begin repairing damaged tissue.
How Exosomes Compare to PRP and Bone Marrow Aspirate
Where PRP and bone marrow aspirate work by concentrating healing agents sourced directly from the patient, exosomes are manufactured externally and work through an entirely different mechanism. Because they contain no living cells, they sidestep many of the risks associated with cell-based therapies. They can be produced with a level of biological consistency that autologous treatments cannot match. That consistency makes them a particularly reliable component of a structured regenerative program. For patients who have plateaued on PRP or conventional injections, exosomes represent a more precise intervention, one that targets cellular behavior at a molecular level rather than simply increasing the local concentration of growth factors.
Where Exosome Therapy Fits in Our Regenerative Program
At our practice, exosome therapy does not exist in isolation. It sits within a regenerative program that also encompasses platelet-rich plasma, bone marrow aspirate, and disk cell and scaffold treatment. Whether exosomes are used as a standalone therapy or layered with other biologics depends entirely on the individual patient's condition, the structures involved, and the degree of degeneration present. Our Bayonne team makes that determination through careful evaluation, not a preset menu of options.